• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    7/12/22 2:27:52 PM ET
    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALDX alert in real time by email

     

    Gainers

    • Sharps Compliance (NASDAQ:SMED) stock increased by 193.5% to $8.37 during Tuesday's regular session. Sharps Compliance's stock is trading at a volume of 3.0 million shares as of 13:30 EST. This is 1500.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $162.5 million.
    • Rhythm Pharmaceuticals (NASDAQ:RYTM) shares increased by 22.81% to $5.76. The current volume of 1.2 million shares is 142.0% of Rhythm Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $290.2 million.
    • Alpha Teknova (NASDAQ:TKNO) shares increased by 20.78% to $9.18. The market value of their outstanding shares is at $257.4 million.
    • Hillstream BioPharma (NASDAQ:HILS) shares moved upwards by 17.47% to $1.19. As of 13:30 EST, Hillstream BioPharma's stock is trading at a volume of 771.7K, which is 60.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.7 million.
    • NuCana (NASDAQ:NCNA) stock rose 16.12% to $0.93. Trading volume for this security as of 13:30 EST is 573.2K, which is 367.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $48.6 million.
    • Aldeyra Therapeutics (NASDAQ:ALDX) stock rose 15.1% to $5.14. As of 13:30 EST, Aldeyra Therapeutics's stock is trading at a volume of 2.7 million, which is 290.9% of its average full-day volume over the last 100 days. The company's market cap stands at $299.9 million.

    Losers

    • Iterum Therapeutics (NASDAQ:ITRM) stock declined by 15.4% to $0.28 during Tuesday's regular session. The current volume of 9.4 million shares is 255.1% of Iterum Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $52.2 million.
    • Assertio Holdings (NASDAQ:ASRT) shares fell 13.59% to $2.8. As of 13:30 EST, this security is trading at a volume of 1.2 million shares, making up 126.0% of its average full-day volume over the last 100 days. The company's market cap stands at $127.2 million.
    • Biotricity (NASDAQ:BTCY) shares decreased by 12.76% to $1.3. Trading volume for Biotricity's stock is 71.1K as of 13:30 EST. This is 62.4% of its average full-day volume over the last 100 days. The company's market cap stands at $66.8 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock declined by 12.07% to $0.46. Trading volume for Quoin Pharmaceuticals's stock is 349.0K as of 13:30 EST. This is 12.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.5 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares declined by 11.9% to $0.22. As of 13:30 EST, this security is trading at a volume of 3.3 million shares, making up 129.8% of its average full-day volume over the last 100 days. The company's market cap stands at $11.5 million.
    • Windtree Therapeutics (NASDAQ:WINT) stock fell 11.88% to $0.42. The current volume of 525.1K shares is 61.4% of Windtree Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $12.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX
    $ASRT
    $BTCY
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/25/2025$136.00Buy
    Citigroup
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/5/2025Outperform → Perform
    Oppenheimer
    Alpha Teknova Inc.
    $TKNO
    7/22/2025$8.00Overweight
    Stephens
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/14/2025$130.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/10/2025$97.00Buy
    Goldman
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/7/2025$88.00Outperform
    Leerink Partners
    Rhythm Pharmaceuticals Inc.
    $RYTM
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

    — Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for QRX003 in Netherton Syndrome — ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on d

    3/11/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    Assertio Holdings, Inc. ("Assertio") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wis

    3/3/26 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

    -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity (HO). This new data set inc

    3/1/26 12:30:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by General Counsel and CCO Terrill Damon

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:35:21 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Lowell Matthew bought $87,616 worth of shares (40,000 units at $2.19), increasing direct ownership by 31% to 168,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:30:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $55,801 worth of shares (26,000 units at $2.15), increasing direct ownership by 11% to 269,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:24:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Rhythm Pharmaceuticals with a new price target

    Citigroup initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $136.00

    11/25/25 8:45:08 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals downgraded by Oppenheimer

    Oppenheimer downgraded Rhythm Pharmaceuticals from Outperform to Perform

    11/5/25 7:28:21 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    SEC Filings

    View All

    SEC Form 8-K filed by Quoin Pharmaceuticals Ltd.

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    3/11/26 4:30:34 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

    144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    3/4/26 4:14:44 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics plc filed SEC Form 8-K: Other Events

    8-K - Iterum Therapeutics plc (0001659323) (Filer)

    3/3/26 4:45:24 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lowell Matthew bought $87,616 worth of shares (40,000 units at $2.19), increasing direct ownership by 31% to 168,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:30:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $55,801 worth of shares (26,000 units at $2.15), increasing direct ownership by 11% to 269,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:24:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $ASRT
    $BTCY
    $ENVB
    Financials

    Live finance-specific insights

    View All

    Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    Assertio Holdings, Inc. ("Assertio") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wis

    3/3/26 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2025. "After another successful year of disciplined execution against our strategic objectives,

    2/26/26 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Manag

    2/26/26 7:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care